

## Jobkeeper s323DB(1) notice

**Melbourne, Australia; 11 November 2021:** Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) provides the attached Jobkeeper Payments Notification in accordance with subsection 323DB(1) of the *Corporations Act 2001 (Cth)*.

---

### About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](https://www.starpharma.com) | [Twitter](https://twitter.com/starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

---

### Media: Sumit Media

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

### Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

### Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

# Jobkeeper Payments Notification

*A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001-jobkeeper payments disclosure by listed entity.*

Date of this notice

11/11/2021

## Listed entity details

Australian Business Number (ABN)  
20078532180

ASX/NSX/SSX issuer code  
SPL

Name of the listed entity  
Starpharma Holdings Limited

## Jobkeeper payments

This notice relates to the financial years ended 30/06/2020 (FY 1) and 30/06/2021 (FY 2).

**The number of individuals for whom the listed entity or a subsidiary of the listed entity received a jobkeeper payment for a jobkeeper fortnight that ended in the financial year** (within the meaning of the Coronavirus Economic Response Package (Payments and Benefits) Rules 2020).

FY 1: 41

FY 2: 42

**The sum of all jobkeeper payments the listed entity, and each subsidiary of the listed entity, received in a jobkeeper fortnight that ended in the financial year.**

FY 1: \$241,500

FY 2: \$534,000

**Has the listed entity or a subsidiary of the listed entity, made one or more voluntary payments (whether or not in the financial year) to the Commonwealth by way of a repayment of jobkeeper payments received by the listed entity or a subsidiary of the listed in the financial year?**

NO

**If the listed entity or a subsidiary of the listed entity has made such a voluntary payment or payments -the sum of those payments:**

FY 1:\$0

FY 2:\$0